Genomic Valley Biotech Ltd (GVBL) — shareholding pattern, promoter holding, financials and share price
About Genomic Valley Biotech Ltd (GVBL)
Genomic Valley Biotech Ltd operates in the Biotechnology industry, within the Healthcare sector. It trades on the NSE as GVBL and on the BSE under scrip code 539206. Its ISIN is INE574D01010.
Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic [1]
Genomic Valley Biotech Limited specializes in biotechnology research, focusing on plant and animal biotechnology, and commercial production of plant tissue-cultured plants for the genetically improved plant market both domestically and internationally.
The company is engaged in high-tech cultivation through controlled environment poly houses and other advanced methods such as NFT and DFT, along with the manufacturing of improved plant varieties using tissue culture methods.
Listed peers in Biotechnology: Beryl Drugs Ltd, Unjha Formulations Ltd, Colinz Laboratories Ltd, Vivanza Biosciences Ltd, Ganga Pharmaceuticals Ltd, Decipher Labs Ltd.
Valuation & Returns
10 Jul 2026At ₹29.92 a share on 10 Jul 2026, Genomic Valley Biotech Ltd (GVBL) was valued at a price-to-earnings ratio of 457.11x against an industry P/E of 36.41x and a price-to-book of 2.35x on a book value of ₹12.76 per share as of Mar 2025. Solomo computes return on equity of 0.51% and return on capital employed of 0.77% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 457.11x
- Industry P/E
- 36.41x
- P/B
- 2.35x
- EPS (TTM)
- ₹0.07
- Book value / share
- ₹12.76
- ROE
- 0.51%
- ROCE
- 0.77%
- ROA
- 0.46%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 14.81%
- 52-week range
- ₹20.1 – ₹53.49
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Genomic Valley Biotech Ltd (GVBL) reported revenue of ₹0.27 crore, net profit of ₹0.03 crore and earnings per share of ₹0.1. That compares with revenue of ₹0.84 crore and net profit of ₹0.36 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹0.04 crore and net profit ₹-0.01 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0.07 | 2.72 | 0.17 | 0.84 | 0.27 |
| Net profit (₹ cr) | -0.01 | 0.65 | 0.02 | 0.36 | 0.03 |
| EPS (₹) | -0.03 | 2.13 | 0.07 | 1.18 | 0.1 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 25.53% | -0.06% | 128.69% | 394.12% |
| Profit growth | - | 4.48% | - | - |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 46.06% of Genomic Valley Biotech Ltd (GVBL) (unchanged from the previous quarter). Market capitalisation was ₹9 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2015.
Largest disclosed public shareholders in Jun 2026: DEEPTI AGGARWAL 11%, AMAR AGGARWAL 9.05%, VIKRAM ASHOKKUMAR JAIN 5.5%, HUF 1.83%, WASP TRADMART PRIVATE LIMITED 1.19%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 46.06% | - | - | - | 53.94% |
| Mar 2026 | 46.06% | - | - | - | 53.94% |
| Dec 2025 | 46.06% | - | - | - | 53.94% |
| Sep 2025 | 46.72% | - | - | - | 53.28% |
| Jun 2025 | 46.72% | - | - | - | 53.28% |
| Mar 2025 | 46.78% | - | - | - | 53.22% |
| Dec 2024 | 46.83% | - | - | - | 53.17% |
| Sep 2024 | 54.67% | - | - | - | 45.33% |